The $132.3M raise provides a multi-year cash runway through key Phase 3 readouts. Monitor Q3 2026 for CHAPTER-3 topline data, which is the primary catalyst. The offering was fully subscribed with underwriter option exercise, indicating strong institutional demand despite dilution.
Price Chart
Executive Summary
Pharvaris closed a $132.3M underwritten offering of 4.46M ordinary shares, including full exercise of the underwriters' option. The proceeds provide a significant cash runway for late-stage clinical programs, including the pivotal Phase 3 CHAPTER-3 study for HAE prevention with topline data expected in Q3 2026.
Key Financial Metrics
Key Facts
- Closed underwritten offering of 4,455,863 ordinary shares at gross proceeds of ~$132.3M
- Underwriters exercised option in full for an additional 581,199 shares
- Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities acted as joint book-running managers
- Proceeds will fund late-stage clinical programs including CHAPTER-3 Phase 3 study for HAE prevention
- Topline data from CHAPTER-3 study anticipated in Q3 2026
- CREAATE Phase 3 study for AAE-C1INH is ongoing
Financial Impact
$132.3M gross proceeds from offering
Risk Factors
- Dilution of ~4.5M shares (approximately 10-15% of pre-offering shares outstanding)
- Clinical trial risk for CHAPTER-3 and CREAATE studies
- No revenue-generating products approved yet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292354 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.07 (+18.38%) |
Sep 14, 2026 17d ago | 144 | $38.06 $35.20 | ▼ −7.51% | ▼ −9.63% | $31.07 (−18.38%) |
Sep 14, 2026 18d ago | Insider Cluster | $38.86 $36.02 | ▼ −7.31% | ▼ −7.41% | $31.07 (−20.06%) |
Sep 11, 2026 21d ago | Insider Cluster | $38.02 $36.37 | ▼ −4.34% | ▼ −4.12% | $31.07 (−18.29%) |
Sep 8, 2026 24d ago | 6-K | $37.84 $38.86 | ▲ +2.70% | ▲ +3.36% | $31.07 (−17.90%) |
Aug 12, 2026 7w ago | 6-K | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 12, 2026 7w ago | Press Release | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 6, 2026 8w ago | Press Release | $34.45 $34.04 | ▼ −1.19% | ▼ −2.40% | $31.07 (−9.83%) |
Jul 6, 2026 12w ago | Press Release | $33.22 $35.07 | ▲ +5.57% | ▲ +5.08% | $31.07 (−6.49%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.86 $35.96 | ▲ +6.20% | ▲ +5.27% | $31.07 (−8.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access